You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
瑞麗醫美(02135.HK)預期中期母公司擁有人應占虧損約800萬元
格隆匯 08-08 18:29

格隆匯8月8日丨瑞麗醫美(02135.HK)公吿,董事會預期集團將錄得:(i)截至2025年6月30日止六個月的收益約人民幣85百萬元(截至2024年6月30日止六個月:收益約人民幣117百萬元);及(ii)截至2025年6月30日止六個月,母公司擁有人應占虧損約人民幣8百萬元(截至2024年6月30日止六個月:母公司擁有人應占虧損約人民幣2百萬元)。

董事會認為,虧損乃主要由於以下原因:(a)截至2025年6月30日止六個月內,由於市場競爭激烈,集團的總收入下滑,較截至2024年6月30日止六個月的總收入減少約人民幣32百萬元,導致醫療美容服務及醫療美容管理諮詢服務分部出現經營性虧損約人民幣2百萬元;(b)於報吿期內,集團購股權開支約為人民幣1百萬元;及(c)為了加快集團的醫療器械產品研發及生產,集團加大對公司間接非全資附屬公司蘇州瑞泉生物醫藥科技有限公司(前稱蘇州詠藍生物醫藥科技有限公司)研發活動的投入。截至2025年6月30日止六個月,蘇州瑞泉的管理費用及研發費用約為人民幣1百萬元。該等開支尚未自報吿期內由此產生的經濟利益中收回。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account